Drug Profile

KJ C2219

Alternative Names: KJ-C2219

Latest Information Update: 30 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CARsgen
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Immunomodulators; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Phase I Non-Hodgkin's lymphoma; Systemic lupus erythematosus; Systemic scleroderma

30 Jun 2025 Phase-I clinical trials in Systemic scleroderma in China (Injection), prior to June 2025 (CARsgen Therapeutics pipeline, June 2025)
16 Jun 2025 Phase-I clinical trials in Systemic lupus erythematosus (Treatment-experienced) in China (Injection) (NCT07031713) (CARsgen Therapeutics pipeline, June 2025)
25 Feb 2025 CARsgen Therapeutics and UCARsgen enters into a licensing agreement for allogeneic CAR-T cell products development in mainland China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com